Related Experiment Video
Updated: Jul 5, 2026
08:13
Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination
Published on: January 20, 2019
Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models
Ruxandra Draghia-Akli1, Amir S Khan, Patricia A Brown
1VGX Pharmaceuticals, 2700 Research Forest Drive, Suite 180, The Woodlands, TX 77381, United States. rdraghia@vgxp.com
Vaccine
|May 3, 2008
Summary
Optimizing DNA vaccine delivery using adaptive constant-current electroporation (EP) enhances expression and immunogenicity. Concentrated DNA formulations and specific EP parameters improve vaccine efficacy in preclinical models, paving the way for human clinical trials.
Area of Science:
- Biotechnology
- Immunology
- Veterinary Medicine
Background:
- DNA vaccines offer a promising platform for disease prevention.
- Optimizing DNA vaccine delivery is crucial for enhancing expression and immunogenicity.
- Electroporation (EP) is a physical method used to improve DNA vaccine delivery.
Purpose of the Study:
- To optimize DNA vaccine delivery using adaptive constant-current electroporation (EP).
- To investigate the impact of various EP parameters on DNA vaccine expression and immunogenicity in preclinical models.
- To identify EP conditions that minimize muscle damage.
Main Methods:
- Experiments were conducted in mice and pigs using adaptive constant-current electroporation.
- Parameters examined included target muscle, delay between plasmid delivery and EP, and DNA vaccine formulation.
- Muscle damage resulting from EP was quantified.
Main Results:
- Concentrated DNA vaccine formulations resulted in significantly better expression and immunogenicity.
- Specific adaptive constant-current EP parameters were identified that enhance DNA vaccine efficacy.
- Conditions limiting muscle damage during EP were determined.
Conclusions:
- Adaptive constant-current electroporation is an effective method for enhancing DNA vaccine delivery and efficacy.
- Optimized formulation and EP parameters are key to successful DNA vaccine application.
- These findings support the advancement of DNA vaccines from animal studies to human clinical trials.
